On Tuesday, the European Court of Justice announced a ruling that denies patents on stem cell research. While it does not disallow scientists from conducting this type of research, it does prevent them from getting patents on stem cell research techniques in Europe. As a result of this ruling, companies will be less likely to invest in new techniques for conducting stem cell research, since the research can be copied without patent protection. Patents on such research will still be available elsewhere in the world, since this decision affects only European scientists. Stem cell research involves obtaining cells from embryos that are left over from fertility treatments and have been donated. Removing the stem cells destroys the embryo, and the cells can then become other cells in the body and be used to treat degenerative diseases. Greenpeace, the organization that objected to the patent in this case, indicated that while it is “not against research on human embryonic stem cells,” it is against “the commercialization of the human body.” What do you think? Is stem cell research conducted with donated embryos really “commercialization of the human body”?